Jaime Pérez de Oteyza
Centro de Estudios Universitarios
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jaime Pérez de Oteyza.
Haematologica | 2010
Josep-Maria Ribera; Albert Oriol; Marcos González; Belén Vidriales; Salut Brunet; Jordi Esteve; Eloy del Potro; Concepción Rivas; M. Moreno; Mar Tormo; Victoria Martin-Reina; Josep Sarrá; Ricardo Parody; Jaime Pérez de Oteyza; Encarna Bureo; Maria-Teresa Bernal
Background Imatinib, given concurrently or alternating with chemotherapy, has improved the response and survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) but relapses are still frequent. The aim of this study was to evaluate the feasibility and results of giving imatinib concurrently with intensive chemotherapy, stem cell transplantation and post-transplant imatinib maintenance therapy in patients with newly diagnosed Ph+ ALL. Design and Methods This was a phase II study of patients with newly diagnosed Ph+ ALL given standard chemotherapy, together with imatinib (400 mg/day) until stem cell transplantation, followed by imatinib maintenance therapy for all patients regardless of the molecular status of the disease. Results Of the 30 patients included, 27 (90%) achieved complete remission, one was resistant to treatment and two died during induction therapy. The percentages of major and complete molecular responses were 86% and 21% after induction, and 81% and 65% after consolidation, respectively. Similar results were observed assessing minimal residual disease by flow cytometry. Of the 27 patients who achieved complete remission, 21 underwent stem cell transplantation (16 allogeneic, 5 autologous). Imatinib (400 mg/day) could be administered after transplantation for a median of 3.9 months in 12 patients, although it was interrupted in 10 patients (in 2 cases because of side effects of the drug). Nine patients relapsed, four before and five after stem cell transplantation and eight patients died of transplant-related causes. With a median follow-up of 4.1 years, the probabilities (95% CI) of disease-free and overall survival were 30% (15% to 45%) and 30% (16% to 45%), respectively. Conclusions These results confirm that imatinib is an effective first-line treatment for adult Ph+ ALL when given concurrently with chemotherapy, making stem cell transplantation feasible in a high proportion of patients. However, post-transplantation imatinib administration was limited, mainly because of transplantation-derived complications rather than drug-specific toxicity.
Blood | 2016
Maria-Victoria Mateos; Joaquin Martinez-Lopez; Miguel-Teodoro Hernández; Enrique-M. Ocio; Laura Rosiñol; Rafael Martínez; Ana-Isabel Teruel; Norma C. Gutiérrez; M. Ramos; Albert Oriol; Joan Bargay; Enrique Bengoechea; Yolanda Gonzalez; Jaime Pérez de Oteyza; Mercedes Gironella; Cristina Encinas; Jesús Martín; Carmen Cabrera; Bruno Paiva; Maria-Teresa Cedena; Noemi Puig; Joan Bladé; Juan-José Lahuerta; Jesús F. San-Miguel
Bortezomib plus melphalan and prednisone (VMP) and lenalidomide plus low-dose dexamethasone (Rd) are 2 standards of care for elderly untreated multiple myeloma (MM) patients. We planned to use VMP and Rd for 18 cycles in a sequential or alternating scheme. Patients (233) with untreated MM, >65 years, were randomized to receive 9 cycles of VMP followed by 9 cycles of Rd (sequential scheme; n = 118) vs 1 cycle of VMP followed by 1 cycle of Rd, and so on, up to 18 cycles (alternating scheme; n = 115). VMP consisted of one 6-week cycle of bortezomib using a biweekly schedule, followed by eight 5-week cycles of once-weekly VMP. Rd included nine 4-week cycles of Rd. The primary end points were 18-month progression free survival (PFS) and safety profile of both schemes. The 18-month PFS was 74% and 80% in the sequential and alternating arms, respectively (P = .21). The sequential and alternating groups exhibited similar hematologic and nonhematologic toxicity. Both arms yielded similar complete response rate (42% and 40%), median PFS (32 months vs 34 months, P = .65), and 3-year overall survival (72% vs 74%, P = .63). The benefit of both schemes was remarkable in patients aged 65 to 75 years. In addition, achieving complete and immunophenotypic response was associated with better outcome. The present approach, based on VMP and Rd, is associated with high efficacy and acceptable toxicity profile with no differences between the sequential and alternating regimens. This trial was registered at www.clinicaltrials.gov as #NCT00443235.
Leukemia & Lymphoma | 2014
Blanca Xicoy; María-José Jiménez; Olga García; Joan Bargay; Violeta Martínez-Robles; Salut Brunet; M.J. Arilla; Jaime Pérez de Oteyza; Rafael Andreu; Francisco-Javier Casaño; C. Cervero; Alicia Bailen; M. Díez; Bernardo Gonzalez; Ana-Isabel Vicente; Carme Pedro; Teresa Bernal; Elisa Luño; Maria-Teresa Cedena; Luis Palomera; Adriana Simiele; José-Manuel Calvo; Victor Marco; Eduardo Gómez; Marta Gómez; David Gallardo; Juan Muñoz; Javier Grau; Josep-Maria Ribera; Luis-Enrique Benlloch
Abstract The tolerability of azacitidine (AZA) allows its administration in elderly patients. The objective of this study was to analyze the clinical and biological characteristics, transfusion independence (TI), overall survival (OS) and toxicity in a series of 107 patients ≥ 75 years of age from the Spanish Registry of Myelodysplastic Syndromes (MDS) treated with AZA. The median age (range) was 78 (75–90) years. According to the World Health Organization (WHO) classification, 86/102 (84%) had MDS, 10/102 (10%) had mixed myeloproferative/myelodysplastic disorder and 6/102 (6%) had acute myeloblastic leukemia. Regarding MDS by the International Prognostic Scoring System on initiation of AZA, 38/84 (45%) were low–intermediate-1 risk and 46/84 (55%) were intermediate-2–high risk. Ninety-five patients (89%) were red blood cell or platelet transfusion dependent. The AZA schedule was 5-0-0 in 39/106 (37%) patients, 5-2-2 in 36/106 (34%) patients and 7 consecutive days in 31/106 (29%) patients. The median number of cycles administered was 8 (range, 1–30). Thirty-eight out of 94 (40%) patients achieved TI. Median OS (95% confidence interval [CI]) was significantly better in patients achieving TI (n = 38) compared to patients who did not (n = 56) (22 [20.1–23.9] months vs. 11.1 [4.8–17.5] months, p = 0.001). No significant differences were observed in TI rate and OS among the three different schedules. With a median follow-up of 14 (min–max, 1–50) months, the median OS (95% CI) of the 107 patients was 18 (12–23) months and the probability of OS (95% CI) at 2 years was 34% (22–46%). Cycles were delayed in 31/106 (29%) patients and 47/101 patients (47%) were hospitalized for infection. These results show that treatment with AZA was feasible and effective in this elderly population, with 40% achieving TI, having a better OS than patients not achieving it. The schedule of AZA administration did not affect efficacy and toxicity.
Journal for ImmunoTherapy of Cancer | 2013
Andres Forero; Mehdi Hamadani; Thomas J. Kipps; Michelle A. Fanale; Antonio Cuneo; Jaime Pérez de Oteyza; Douglas E. Gladstone; Marc André; Naresh Bellam; Trishna Goswami; Ramy Ibrahim; Amy Schneider; Meina Liang; Steven Eck; Nairouz Elgeioushi; Ronald Herbst; Bruce D. Cheson
and 13 had stable disease. Commonly reported adverse events (AEs) in MEDI-551 pts were infusion-related reactions (IRRs; 62%), nausea (23%), pyrexia (23%), and neutropenia (23%) in the 26 ph 1/2 pts; in the 29 ph 2 pts, they were nausea (62%), IRRs (31%), pyrexia (28%), chills (28%), and fatigue (28%). 11 pts had ≥ grade 3 AEs in the ph 1/2 study and 16 in the ph 2. Common treatmentrelated AEs: IRRs (58%) and nausea (12%) in the ph 1/2; nausea (52%), IRRs (28%), chills (24%), and fatigue (24%) in the ph 2. Three treatment-unrelated AEs of general health deterioration (ph 1/2), subarachnoid hemorrhage (ph 1/2), and sepsis (ph 2), resulted in death. Conclusions MEDI-551 as a single agent demonstrated B-cell depletion, increased serum BAFF levels, clinical activity, and an acceptable risk-benefit profile in relapsed/refractory CLL pts. Preliminary results of the ongoing ph 2 study of MEDI-551+bendamustine demonstrated an acceptable safety profile.
Haematologica | 2018
Yanira Ruiz-Heredia; Beatriz Sánchez-Vega; Esther Onecha; Santiago Barrio; Rafael Alonso; Jose Carlos Martínez-Ávila; Isabel Cuenca; Xabier Agirre; Esteban Braggio; Miguel-T Hernandez; Rafael Martínez; Laura Rosiñol; Norma C. Gutiérrez; Marisa Martin-Ramos; Enrique M. Ocio; María Asunción Echeveste; Jaime Pérez de Oteyza; Albert Oriol; Joan Bargay; Mercedes Gironella; Rosa Ayala; Joan Bladé; Maria-Victoria Mateos; Klaus Martin Kortüm; Keith Stewart; Ramón García-Sanz; Jesús F. San Miguel; Juan José Lahuerta; Joaquin Martinez-Lopez
Next-generation sequencing has substantially improved our understanding of the genomic landscape of multiple myeloma; however, the application of this technology has been confined mostly to research studies. Here, we report on a customized panel to characterize the mutational profile of 79 newly diagnosed patients with multiple myeloma, older than 65 years and who were not transplant candidates, applying the highest read depth to date that has been used for equivalent studies in multiple myeloma. Overall, we identified 53 genes mutated in 85% of patients, including KRAS, NRAS, BRAF, DIS3 and TP53, and found a complex subclonal structure. In addition, the total number of mutations, as well as mutations in TP53 and the Cereblon pathway, were negatively associated with survival. The latter result is particularly noteworthy as patients enrolled in this phase II clinical trial were treated with lenalidomide, which targets this pathway. Our next-generation sequencing strategy not only identified a group of patients with poor outcome, but also provided an extensive genetic profile that should prove useful in the search for new biomarkers and therapeutic targets in multiple myeloma, at an affordable price and with a small amount of sample, which are indispensable features for translating personalized medicine protocols to clinical practice.
Haematologica | 2018
Esther Onecha; María Linares; Inmaculada Rapado; Yanira Ruiz-Heredia; Pilar Martínez-Sánchez; Teresa Cedena; Marta Pratcorona; Jaime Pérez de Oteyza; Pilar Herrera; Eva Barragán; Pau Montesinos; Jose Antonio Garcia Vela; Elena Magro; Eduardo Anguita; Angela Figuera; Rosalía Riaza; Pilar Martinez-Barranco; Beatriz Sánchez-Vega; Josep Nomdedeu; Miguel Gallardo; Joaquin Martinez-Lopez; Rosa Ayala
A high proportion of patients with acute myeloid leukemia who achieve minimal residual disease negative status ultimately relapse because a fraction of pathological clones remains undetected by standard methods. We designed and validated a high-throughput sequencing method for minimal residual disease assessment of cell clonotypes with mutations of NPM1, IDH1/2 and/or FLT3-single nucleotide variants. For clinical validation, 106 follow-up samples from 63 patients in complete remission were studied by sequencing, evaluating the level of mutations detected at diagnosis. The predictive value of minimal residual disease status by sequencing, multiparameter flow cytometry, or quantitative polymerase chain reaction analysis was determined by survival analysis. The sequencing method achieved a sensitivity of 10−4 for single nucleotide variants and 10−5 for insertions/deletions and could be used in acute myeloid leukemia patients who carry any mutation (86% in our diagnostic data set). Sequencing–determined minimal residual disease positive status was associated with lower disease-free survival (hazard ratio 3.4, P=0.005) and lower overall survival (hazard ratio 4.2, P<0.001). Multivariate analysis showed that minimal residual disease positive status determined by sequencing was an independent factor associated with risk of death (hazard ratio 4.54, P=0.005) and the only independent factor conferring risk of relapse (hazard ratio 3.76, P=0.012). This sequencing-based method simplifies and standardizes minimal residual disease evaluation, with high applicability in acute myeloid leukemia. It is also an improvement upon flow cytometry- and quantitative polymerase chain reaction-based prediction of outcomes of patients with acute myeloid leukemia and could be incorporated in clinical settings and clinical trials.
Cancer Chemotherapy and Pharmacology | 2013
Eric Van Den Neste; Bruno Cazin; Ann Janssens; Eva González-Barca; María José Terol; Vincent Levy; Jaime Pérez de Oteyza; Pierre Zachee; Andrew Saunders; Mercè de Frias; Clara Campàs
Blood | 2013
Andres Forero-Torres; Mehdi Hamadani; Michelle A. Fanale; Celeste M. Bello; Thomas J. Kipps; Fritz Offner; Gregor Verhoef; Massimo Federico; Stephanie A. Gregory; Anne Sonet; Sarit Assouline; Jaime Pérez de Oteyza; José Francisco Tomás; Antonio Cuneo; Nairouz Elgeioushi; Trishna Goswami; Ramy Ibrahim; Ronald Herbst; Bruce D. Cheson
Journal of Clinical Oncology | 2013
Mehdi Hamadani; Andres Forero; Thomas J. Kipps; Michelle A. Fanale; Antonio Cuneo; Jaime Pérez de Oteyza; Douglas E. Gladstone; Trishna Goswami; Ramy Ibrahim; Meina Liang; Steven Eck; Nairouz Elgeioushi; Ronald Herbst; Bruce D. Cheson
Blood | 2015
David Valcárcel; Amit Verma; Uwe Platzbecker; Valeria Santini; Aristoteles Giagounidis; María Díez-Campelo; Jan Janssen; Richard F. Schlenk; Gianluca Gaidano; Jaime Pérez de Oteyza; Ann Cleverly; Alan Y Chiang; Michael Lahn; Durisala Desiaih; Susan C. Guba; Alan F. List; Rami S. Komrokji